This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n7http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/ontology/domain/vavai/
n5http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F03%3A00009445%21RIV08-MSM-14110___/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F03%3A00009445%21RIV08-MSM-14110___
rdf:type
n14:Vysledek skos:Concept
dcterms:description
The randomized multicenter trial was conducted to compare the tolerability of gemcitabine plus cisplatin GP vs. gemcitabine plus carboplatin GC in chemonaive stage IIIb and IV pts. The enrolled pts, 87 in the GP branch and 89 in GC branch, were balanced demographically and for disease characteristics. Results show that that both regimens were comparable. GC may offer acceptable option for patients unable to receive cisplatin. The randomized multicenter trial was conducted to compare the tolerability of gemcitabine plus cisplatin GP vs. gemcitabine plus carboplatin GC in chemonaive stage IIIb and IV pts. The enrolled pts, 87 in the GP branch and 89 in GC branch, were balanced demographically and for disease characteristics. Results show that that both regimens were comparable. GC may offer acceptable option for patients unable to receive cisplatin. The randomized multicenter trial was conducted to compare the tolerability of gemcitabine plus cisplatin GP vs. gemcitabine plus carboplatin GC in chemonaive stage IIIb and IV pts. The enrolled pts, 87 in the GP branch and 89 in GC branch, were balanced demographically and for disease characteristics. Results show that that both regimens were comparable. GC may offer acceptable option for patients unable to receive cisplatin.
dcterms:title
Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial
skos:prefLabel
Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial
skos:notation
RIV/00216224:14110/03:00009445!RIV08-MSM-14110___
n4:strany
245-367
n4:aktivita
n8:Z
n4:aktivity
Z(MSM 141100003), Z(MZ06526970501)
n4:cisloPeriodika
3
n4:dodaniDat
n12:2008
n4:domaciTvurceVysledku
n6:2428245
n4:druhVysledku
n18:J
n4:duvernostUdaju
n11:S
n4:entitaPredkladatele
n13:predkladatel
n4:idSjednocenehoVysledku
608033
n4:idVysledku
RIV/00216224:14110/03:00009445
n4:jazykVysledku
n16:eng
n4:klicovaSlova
non small cell lung cancer; gemcitabine; carboplatin; cisplatin; phase III trial
n4:klicoveSlovo
n10:carboplatin n10:cisplatin n10:phase%20III%20trial n10:non%20small%20cell%20lung%20cancer n10:gemcitabine
n4:kodStatuVydavatele
CZ - Česká republika
n4:kontrolniKodProRIV
[BF01E093212D]
n4:nazevZdroje
Lung Cancer
n4:obor
n17:FC
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
10
n4:rokUplatneniVysledku
n12:2003
n4:svazekPeriodika
41
n4:tvurceVysledku
Petruželka, Luboš Zatloukal, Petr Pešek, Miloš Sixtová, Dimka Kolek, Vítězslav Skřičková, Jana Zemanová, Milada Grygárková, Ivona Roubec, Jaromír Foitů, Hana
n4:zamer
n5:MZ06526970501 n5:MSM%20141100003
s:issn
0169-5002
s:numberOfPages
22
n7:organizacniJednotka
14110